*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2026 | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · preclinical | PMID 41490200 |
| 2026 | Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians The American journal of sports medicine · preclinical | PMID 41476424 |
| 2025 | Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity The Journal of infectious diseases · human | PMID 39813152 |
| 2024 | Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors AIDS (London, England) · human | PMID 38905488 |
| 2023 | Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial Journal of clinical and translational science · preclinical | PMID 36845310 |
| 2021 | Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach Scientific reports · preclinical | PMID 34006921 |
| 2021 | Tesamorelin improves fat quality independent of changes in fat quantity AIDS (London, England) · preclinical | PMID 33756511 |
| 2020 | Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD JCI insight · human | PMID 32701508 |
| 2017 | Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV AIDS (London, England) · preclinical | PMID 28832410 |
| 2016 | · preclinical | PMID 30896905 |
| 2016 | · preclinical | PMID 30920787 |
| 2015 | Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects Clinical pharmacokinetics · human | PMID 25358450 |
| 2012 | Tesamorelin · preclinical | PMID 31644039 |
| 2012 | Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy The Annals of pharmacotherapy · preclinical | PMID 22298602 |
| 2011 | Tesamorelin Nature reviews. Drug discovery · preclinical | PMID 21283099 |
| 2011 | Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy Drugs · preclinical | PMID 21668043 |
| 2011 | Spotlight on tesamorelin in HIV-associated lipodystrophy BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · preclinical | PMID 22050344 |
| 2010 | Tesamorelin update BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation · preclinical | PMID 21591600 |
| 2009 | Tesamorelin, a human growth hormone releasing factor analogue Expert opinion on investigational drugs · preclinical | PMID 19243281 |
| 2006 | Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor Current opinion in investigational drugs (London, England : 2000) · preclinical | PMID 17086939 |
Tesamorelin (Tesamorelin (stabilised GHRH analogue)). Synthetic stabilised analogue of human growth-hormone-releasing hormone. Stimulates endogenous GH and IGF-1; clinically reduces visceral adipose tissue.
Commonly discussed uses: HIV-associated lipodystrophy (approved), visceral fat reduction (research/off-label). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Synthetic stabilised analogue of human growth-hormone-releasing hormone. Stimulates endogenous GH and IGF-1; clinically reduces visceral adipose tissue.
Reported considerations: arthralgia, injection-site reactions, fluid retention, glucose intolerance with chronic use. There is both human and animal/preclinical research, though the depth and quality vary by indication. FDA-approved (Egrifta) for a specific indication. Off-label/grey-market use is not the approved product. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 1mg/day, typical 2mg/day SC (approved dose), high 2mg/day. Administration: subcutaneous. Half-life: ~25-40 min (effect via GH pulse).
Australian status: Not ARTG-registered; prescription if compounded. FDA-approved (Egrifta) for a specific indication. Off-label/grey-market use is not the approved product. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: approved product reconstituted per label; research vials vary; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): clinically used standalone. Stacking increases interaction/safety uncertainty.